(VIANEWS) – PANORO ENERGY (PEN.OL), ELIS (ELIS.PA), OKEA (OKEA.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. PANORO ENERGY (PEN.OL)
1574% sales growth and 16.05% return on equity
Panoro Energy ASA, an independent exploration and production company, engages in the exploration, development, and production of oil and gas properties in Africa. It holds assets in the Equatorial Guinea, Gabon, Tunisia, and South Africa. The company was incorporated in 2009 and is based in London, the United Kingdom.
Earnings Per Share
As for profitability, PANORO ENERGY has a trailing twelve months EPS of kr3.25.
PE Ratio
PANORO ENERGY has a trailing twelve months price to earnings ratio of 7.94. Meaning, the purchaser of the share is investing kr7.94 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.05%.
Sales Growth
PANORO ENERGY’s sales growth is 22.5% for the ongoing quarter and 1574% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 11.7%, now sitting on 236.15M for the twelve trailing months.
More news about PANORO ENERGY.
2. ELIS (ELIS.PA)
77.2% sales growth and 9.02% return on equity
Elis SA provides flat linen, workwear, and hygiene and well-being solutions in France, Central Europe, Scandinavia, Eastern Europe, the United Kingdom, Ireland, Latin America, Southern Europe, and internationally. The company offers table, bed, kitchen, patient, and bath linens; workwear and personal protective equipment; beverage solutions, such as water coolers and accessories, cups and bottles, and coffee machines; floor protection mats and mops; industrial wipers; and pest and rodent control, insect control, or disinfection services. It also provides washroom hygiene services, such as hand washing and drying, toilet hygiene and urinals, lavatories, and air fragrancing; and reusable cleanroom garments, footwear, goggles, and related contamination control solutions, as well as cleaning systems. In addition, the company offers various solutions for collection and disposal of infectious waste, as well as laundry facilities. It primarily serves the catering, accommodation, healthcare and social welfare, industries, trade and retail, and services sectors, as well as public authorities and administration. Elis SA was founded in 1883 and is headquartered in Saint-Cloud, France.
Earnings Per Share
As for profitability, ELIS has a trailing twelve months EPS of €1.19.
PE Ratio
ELIS has a trailing twelve months price to earnings ratio of 14.85. Meaning, the purchaser of the share is investing €14.85 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.02%.
Volume
Today’s last reported volume for ELIS is 70709 which is 77.86% below its average volume of 319419.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on May 30, 2023, the estimated forward annual dividend rate is 0.41 and the estimated forward annual dividend yield is 2.66%.
More news about ELIS.
3. OKEA (OKEA.OL)
74.6% sales growth and 32.98% return on equity
OKEA ASA, an oil and gas company, engages in the development and production of oil and gas in the Norwegian continental shelf. The company holds 44.56% interests in Draugen, 12% interests in Gjøa, 9.2385% interests in Ivar Aasen, 6% interests in Nova, and 15% interests in Yme assets. OKEA ASA was incorporated in 2015 and is headquartered in Trondheim, Norway.
Earnings Per Share
As for profitability, OKEA has a trailing twelve months EPS of kr6.27.
PE Ratio
OKEA has a trailing twelve months price to earnings ratio of 4.76. Meaning, the purchaser of the share is investing kr4.76 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 32.98%.
Yearly Top and Bottom Value
OKEA’s stock is valued at kr29.84 at 01:20 EST, way under its 52-week high of kr41.36 and way higher than its 52-week low of kr25.85.
Volume
Today’s last reported volume for OKEA is 531709 which is 3.27% above its average volume of 514837.
More news about OKEA.
4. SEADRILL (SDRL.OL)
55% sales growth and 8.93% return on equity
Seadrill Limited provides offshore contract drilling services to the oil and gas industry worldwide. It operates in three segments: Harsh Environment, Floaters, and Jack-ups Rigs. The company owns and operates drill ships, semi-submersible rigs, and jack-up rigs for operations in shallow and ultra-deep-water in benign and harsh environments. It serves oil super-majors, state-owned national oil companies, and independent oil and gas companies. Seadrill Limited was formerly known as Seadrill 2021 Limited. The company was incorporated in 2005 and is headquartered in Hamilton, Bermuda.
Earnings Per Share
As for profitability, SEADRILL has a trailing twelve months EPS of kr659.1.
PE Ratio
SEADRILL has a trailing twelve months price to earnings ratio of 0.67. Meaning, the purchaser of the share is investing kr0.67 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.93%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 58%, now sitting on 1.28B for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
SEADRILL’s EBITDA is 224.29.
Volume
Today’s last reported volume for SEADRILL is 22042 which is 82.84% below its average volume of 128484.
Moving Average
SEADRILL’s value is below its 50-day moving average of kr462.74 and under its 200-day moving average of kr443.20.
More news about SEADRILL.
5. BW LPG (BWLPG.OL)
31.1% sales growth and 20.16% return on equity
BW LPG Limited, an investment holding company, engages in shipowning and chartering activities worldwide. The company operates through Shipping and Product Services segments. It is involved in the transportation of liquefied petroleum gas to oil companies, and trading and utility companies. The company also offers integrated liquified petroleum gas (LPG) delivery services directly to buyers and receivers. It owns and operates LPG vessels and a fleet of very large gas carriers. The company was formerly known as BW Gas LPG Holding Limited and changed its name to BW LPG Limited in September 2013. BW LPG Limited was founded in 1935 and is headquartered in Singapore.
Earnings Per Share
As for profitability, BW LPG has a trailing twelve months EPS of kr33.31.
PE Ratio
BW LPG has a trailing twelve months price to earnings ratio of 4.67. Meaning, the purchaser of the share is investing kr4.67 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.16%.
Yearly Top and Bottom Value
BW LPG’s stock is valued at kr155.40 at 01:20 EST, way higher than its 52-week high of kr121.70.
Revenue Growth
Year-on-year quarterly revenue growth grew by 206.6%, now sitting on 2.17B for the twelve trailing months.
More news about BW LPG.
6. NAVAMEDIC (NAVA.OL)
17.8% sales growth and 11.97% return on equity
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, obesity, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr1.18.
PE Ratio
NAVAMEDIC has a trailing twelve months price to earnings ratio of 31.36. Meaning, the purchaser of the share is investing kr31.36 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.97%.
Sales Growth
NAVAMEDIC’s sales growth is 17.3% for the current quarter and 17.8% for the next.
More news about NAVAMEDIC.
7. VISTIN PHARMA (VISTN.OL)
6.6% sales growth and 16.03% return on equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. The company was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr1.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 21.4. Meaning, the purchaser of the share is investing kr21.4 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.03%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 30.8%, now sitting on 438.54M for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
VISTIN PHARMA’s EBITDA is 2.33.
Yearly Top and Bottom Value
VISTIN PHARMA’s stock is valued at kr21.40 at 01:20 EST, way under its 52-week high of kr25.10 and way higher than its 52-week low of kr14.05.
Moving Average
VISTIN PHARMA’s value is under its 50-day moving average of kr22.96 and under its 200-day moving average of kr22.00.
More news about VISTIN PHARMA.
